Filing Flows › bioAffinity Technologies (BIAF) › Q2 2026 › vs Q1 2026
bioAffinity Technologies (BIAF) Q2 2026 vs Q1 2026 (quarter over quarter)
bioAffinity Technologies's revenue rose $159K (+12%) from $1.4M in Q1 2026 to $1.5M in Q2 2026. The biggest changes: Laboratory Services +$160K (+12%); Other Revenues +$424 (+203%).
bioAffinity Technologies, Q2 2026: revenue $1.5M (+19% year over year), operating margin -220.8%, net loss $3.4M, operating cash flow −$3.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Health Care, Patient Service | $1.2M | $1.1M | $162K | +15% |
| Histology Service Fees | $248K | $251K | −$2K | -0.9% |
| Medical Director Fees | $18K | $17K | $83 | +0.5% |
| Laboratory Services | $1.5M | $1.4M | $160K | +12% |
| Other Revenues | $1K | $209 | $424 | +203% |
| Revenue | $1.5M | $1.4M | $159K | +12% |
| Net loss | $3.4M | $3.6M | −$265K | -7% |
| Costs & expenses | $4.9M | $5.0M | −$105K | -2% |
| Operating costs | $4.8M | $5.0M | −$123K | -2% |
| Interest & other, net | $31K | $14K | $18K | +129% |
| Research & development | $362K | $350K | $12K | +3% |
| SG&A | $2.9M | $3.2M | −$383K | -12% |
| Other operating costs | $1.6M | $1.4M | $248K | +18% |
| Operating cash sources | $4.0M | $3.4M | $692K | +21% |
| Depreciation & amortization | $62K | $115K | −$53K | -46% |
| Share-based compensation | $785K | $14K | $771K | 55× |
| Cash used in operations | $3.2M | $3.2M | −$26K | -0.8% |
| Net loss absorbed | $3.4M | $3.6M | −$265K | -7% |
| Working capital & other | $682K | −$275K | $956K | — |
Questions
How much did bioAffinity Technologies's revenue grow quarter over quarter in Q2 2026?
bioAffinity Technologies's revenue rose $159K (+12%) from $1.4M in Q1 2026 to $1.5M in Q2 2026.
What drove bioAffinity Technologies's revenue change in Q2 2026?
Laboratory Services +$160K (+12%); Other Revenues +$424 (+203%).